The last Phase II announcement (released at 9:02 am on Monday, 18 December) was titled "P2 trial shows significant improvements in Phelan-McDermid". The key points were that "significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures" and "NNZ-2591 was safe and well tolerated, with no clinically significant changes in laboratory values or other safety parameters during treatment".
The share price closed up $5.06 (29.52%). It will be interesting to see how today's announcement compares in substance and effect on the share price. As others have noted, there is a case to be made that positive results today would be more valuable than the last announcement, since it would indicate that NNZ-2591 has potential across multiple indications.
- Forums
- ASX - By Stock
- Share Price
The last Phase II announcement (released at 9:02 am on Monday,...
-
-
- There are more pages in this discussion • 455 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.81 |
Change
-0.170(0.85%) |
Mkt cap ! $2.553B |
Open | High | Low | Value | Volume |
$20.11 | $20.14 | $19.63 | $1.074M | 53.97K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 64 | $19.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.82 | 109 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 155 | 19.740 |
1 | 139 | 19.730 |
4 | 200 | 19.720 |
4 | 255 | 19.710 |
3 | 2142 | 19.700 |
Price($) | Vol. | No. |
---|---|---|
19.770 | 147 | 3 |
19.780 | 64 | 1 |
19.790 | 142 | 1 |
19.800 | 790 | 2 |
19.810 | 131 | 1 |
Last trade - 10.21am 25/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |